Target specific cross-linked heteroantibodies
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsDavid M. Segal, Pilar Perez
Life of this patent
Estimating the term…
Abstract
The present invention discloses a target specific cross-linked heteroantibody and a method of producing the same. The cross-linked heteroantibodies of the present invention can cause normal autologous cells of the immune system to destroy any unwanted cell for which an antibody is available. Treatment or control of tumors, viral infected cells, fungi, bacteria, parasites and the like is now made possible through the use of the heteroantibody complex of the present invention.
Claims6
Cross-linked antibody heteroaggregates wherein one antibody of the heteroaggregate binds specifically with a receptor entity on a cytotoxic cell and a second antibody of the heteroaggregate binds specifically with a surface entity on a cell different from and to be lysed by the cytotoxic cell.
A method of destroying target cells in a mammalian host comprising administering to said host cytolytic amount of cross-linked heteroantibodies.
A method of producing target specific heteroantibodies comprising cross-linking a first antibody directed against a receptor entity on a cytotoxic cell with a second antibody directed against a surface component of a target cell.
Dependencies are inferred from the claim text.